- Home
- INSM vs VRSN Comparison
INSM vs VRSN Comparison
Compare INSM & VRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSM
- VRSN
- Stock Information
- Founded
- INSM 1988
- VRSN 1995
- Country
- INSM United States
- VRSN United States
- Employees
- INSM N/A
- VRSN N/A
- Industry
- INSM Biotechnology: Pharmaceutical Preparations
- VRSN EDP Services
- Sector
- INSM Health Care
- VRSN Technology
- Exchange
- INSM Nasdaq
- VRSN Nasdaq
- Market Cap
- INSM 29.0B
- VRSN 27.1B
- IPO Year
- INSM 2000
- VRSN 1998
- Fundamental
- Price
- INSM $189.60
- VRSN $239.80
- Analyst Decision
- INSM Strong Buy
- VRSN Buy
- Analyst Count
- INSM 19
- VRSN 3
- Target Price
- INSM $171.12
- VRSN $275.00
- AVG Volume (30 Days)
- INSM 2.1M
- VRSN 1.0M
- Earning Date
- INSM 10-30-2025
- VRSN 10-23-2025
- Dividend Yield
- INSM N/A
- VRSN 1.28%
- EPS Growth
- INSM N/A
- VRSN N/A
- EPS
- INSM N/A
- VRSN 8.58
- Revenue
- INSM $447,022,000.00
- VRSN $1,626,700,000.00
- Revenue This Year
- INSM $32.08
- VRSN $8.13
- Revenue Next Year
- INSM $125.86
- VRSN $2.97
- P/E Ratio
- INSM N/A
- VRSN $27.96
- Revenue Growth
- INSM 30.34
- VRSN 5.47
- 52 Week Low
- INSM $60.40
- VRSN $175.62
- 52 Week High
- INSM $197.08
- VRSN $310.60
- Technical
- Relative Strength Index (RSI)
- INSM 76.69
- VRSN 30.75
- Support Level
- INSM $154.79
- VRSN $231.05
- Resistance Level
- INSM $168.22
- VRSN $256.99
- Average True Range (ATR)
- INSM 6.44
- VRSN 9.13
- MACD
- INSM 1.81
- VRSN -2.29
- Stochastic Oscillator
- INSM 82.31
- VRSN 32.66
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
About VRSN VeriSign Inc.
VeriSign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.